

Visible-Light-Mediated Synthesis of Amides from Aldehydes and Amines via in Situ Acid Chloride Formation


Naeem Iqbal[†] and Eun Jin Cho^{*‡}

[†]Department of Chemistry and Applied Chemistry, Hanyang University, Ansan 426-791, Republic of Korea

[‡]Department of Chemistry, Chung-Ang University, Seoul 156-756, Republic of Korea

S Supporting Information

ABSTRACT: An efficient visible-light photocatalysis-based one-pot amide synthesis method was developed; visible-light irradiation of a mixture of an aldehyde, *tert*-butyl hydrogen peroxide, and *N*-chlorosuccinimide using a Ru(bpy)₃Cl₂ photocatalyst afforded an acid chloride, which subsequently reacted with amine to yield the corresponding amide. The reaction was used to synthesize moclobemide and a D3 receptor intermediate.



INTRODUCTION

The amide bond is one of the most important bonds in biological macromolecules, and almost 25% of the drug molecules contain an amide bond.¹ Because of the high stability, polarity, and conformational diversity of amide bonds, they have been used in synthetic intermediates to functional materials.^{1,8} Owing to the importance of amide bonds, intensive efforts have been made to develop methods for the construction of the amide bonds. Conventionally, amide bonds are constructed by coupling of carboxylic acid derivatives with amines using certain activating groups [Figure 1 (1)].² Recently, a plethora of methods have been developed for the construction of amide bonds, including the transition-metal-catalyzed³ and *N*-heterocyclic carbene (NHC)-catalyzed⁴ oxidative amidation of aldehydes with amines.^{5–7} However, these direct oxidative amidation of aldehydes has some limitations, mainly the limited substrate scope of amines, and thus the acylation of amines by activated acid derivatives is still the major method for the synthesis of amides. Therefore, alternative efforts have been made for the conversion of aldehydes to activated intermediates that can be utilized in situ for the synthesis of amides. Recently, Yamamoto, Barbas, and De Luca independently reported the synthesis of amides from aldehydes through the formation of activated intermediates via acyl radicals [Figure 1 (2)].^{8–10} The facile synthesis of active intermediates from aldehydes prompted us to develop a visible-light-induced one-pot method for the synthesis of amides. In the process, an acyl radical generated from an aldehyde by visible-light photocatalysis using *tert*-butyl hydrogen peroxide (TBHP) as the oxidant was converted to the corresponding acid chloride intermediate by abstracting a Cl radical from *N*-chlorosuccinimide (NCS).^{11,12} Then, the addition of an amine to the acid chloride intermediate afforded the corresponding amide [Figure 1 (3)].

RESULTS AND DISCUSSION

First, benzaldehyde (**1a**) was converted into benzoyl chloride using TBHP and NCS as the source of Cl in CH₃CN, and only

30% of benzoyl chloride (**2a**) was obtained (Table 1, entry 1). We envisioned that the combined use of visible-light photocatalytic conditions would accelerate the reaction since TBHP can produce radicals under visible-light conditions.^{13,14} To our delight, the use of Ru(bpy)₃Cl₂ under visible-light irradiation increased the yield of **2a** to 78% (Table 1, entry 2). A control experiment showed that the reaction requires visible-light irradiation for a satisfactory conversion of benzaldehyde to benzoyl chloride (Table 1, entry 3). A decrease in the amount of NCS decreased the yield of the reaction, and a further increase in the amount of NCS did not increase the yield (Table 1, entries 4–6). On the other hand, the yield of the reaction increased with a lesser amount of TBHP; even a catalytic amount of TBHP was effective, contrary to the previous report,¹² indicating that TBHP either can be regenerated during the course of the reaction or acts as an initiator (Table 1, entries 7–11).

The use of *N*-bromosuccinimide (NBS) instead of NCS afforded a mixture of undesired products because of the higher reactivity of benzoyl bromide compared to benzoyl chloride (Table 1, entry 12). Different photocatalysts including Ru(phen)₃Cl₂, *fac*-Ir(ppy)₃, *fac*-Ir(dFppy)₃, and Ir(dtbbpy)(ppy)₂PF₆ were investigated; they showed a similar reactivity. Among the catalysts, Ru(bpy)₃Cl₂ was selected because of its low cost and easy availability. CH₃CN was the best solvent (Table 1, entries 8 and 13–15). The concentration studies showed that the use of a 0.25 M concentration provided the best results (Table 1, entries 8, 16, and 17). Although a satisfactory conversion was achieved even by using 0.1 mol % of the photocatalyst, 1 mol % of the photocatalyst was selected for further studies for the reproducible results (Table 1, entries 8 and 18–20). When O₂ was used as the oxidant, the yield decreased significantly (Table 1, entry 21).

With the optimized conditions for the conversion of aldehydes to acid chlorides, a one-pot method was developed

Received: November 30, 2015

Published: February 2, 2016





Figure 1. Amide bond formation via active intermediates.


Table 1. Oxidation of Aldehyde to Acid Halide^a

entry	oxidant (equiv)	equiv of NCS	solvent	variations	yield (%) ^b 2a
1	^t BuOOH (4.0)	3.0	CH ₃ CN	no Ru(bpy) ₃ Cl ₂	30
2	^t BuOOH (4.0)	3.0	CH ₃ CN		78
3	^t BuOOH (4.0)	3.0	CH ₃ CN	no light	32
4	^t BuOOH (4.0)	1.5	CH ₃ CN		17
5	^t BuOOH (4.0)	2.0	CH ₃ CN		56
6	^t BuOOH (4.0)	3.5	CH ₃ CN		70
7	^t BuOOH (2.5)	3.0	CH ₃ CN		82
8	^t BuOOH (1.3)	3.0	CH ₃ CN		84 ^c
9	^t BuOOH (1.0)	3.0	CH ₃ CN		80
10	^t BuOOH (0.6)	3.0	CH ₃ CN		75
11	^t BuOOH (0.25)	3.0	CH ₃ CN		68
12	^t BuOOH (1.3)	3.0	CH ₃ CN	NBS (3.0 equiv)	46 ^d
13	^t BuOOH (1.3)	3.0	CH ₂ Cl ₂		84
14	^t BuOOH (1.3)	3.0	DMF		0
15	^t BuOOH (1.3)	3.0	CH ₃ OH		38
16	^t BuOOH (1.3)	3.0	CH ₃ CN	0.25 M	85
17	^t BuOOH (1.3)	3.0	CH ₃ CN	0.1 M	64
18	^t BuOOH (1.3)	3.0	CH ₃ CN	2.0 mol % cat.	84
19	^t BuOOH (1.3)	3.0	CH ₃ CN	0.5 mol % cat.	80
20	^t BuOOH (1.3)	3.0	CH ₃ CN	0.1 mol % cat.	77
21	O ₂	3.0	CH ₃ CN		trace
22		3.0	CH ₃ CN	degassed CH ₃ CN	0

^aReaction scale: **1a** (0.1 mmol). ^bYields based on GCMS using dodecane as the internal standard. ^cAddition of benzyl amine afforded the corresponding amide in 78% yield. ^dYield of benzoyl bromide, which was formed along with benzoic acid and *tert*-butyl ester.

for the synthesis of amides. The addition of benzyl amine to a reaction mixture of benzoyl chloride (**2a**) afforded *N*-benzylbenzamide (**3a**) in 78% yield. This one-pot method was applied for the synthesis of amides from diverse benzaldehyde

derivatives **1** (Table 2). The reactions of aldehydes bearing both electron-rich and electron-deficient aryl substituents proceeded smoothly, affording the corresponding amides **3** in good yields. The substituents at the ortho position of the aryl ring did not

Table 2. Amide Synthesis from Aldehydes via Acid Chlorides: Substrate Scope with Respect to Benzaldehydes^{a,b}


^aReaction scale: **1** (1.0 mmol), benzyl amine (1.5 mmol). ^bIsolated yields based on the average of two runs.

affect the reactivity (**3b** and **3i**). The reaction tolerated the presence of a nitrile group (**3k**) and halides including fluoro (**3g**), chloro (**3h**, **3i**), and bromo (**3j**). However, some side reactions were also observed. In the reactions of **1b**, **1c**, and **1d**, the benzylic chlorination afforded 5–10% of chlorinated products along with the desired amides **3b**, **3c**, and **3d**, respectively. In the reaction of **1f**, aryl chlorinated products were also detected. Aliphatic aldehydes were not suitable substrates because the decarbonylative products were obtained.¹⁵ This is probably because of the lower stability of aliphatic acyl radicals compared to the benzoyl radical, causing the degradation of radicals before the abstraction of a chlorine radical from NCS.

Further, we studied the substrate scope with respect to different amines for the synthesis of amides (Table 3). Both aromatic and aliphatic amines participated well in the reaction. In general, benzyl amines (**4e** and **4f**) showed better reactivity. The successful amide formation with an aminopyridine (**4d**) indicates that the reaction can be applied to the synthesis of amide bonds containing heterocycles, important structural motifs in many applications including pharmaceuticals.

The facile reaction developed in this study prompted us to synthesize some drug molecules using the reaction conditions. An antidepressant moclobemide (**6**)¹⁶ was synthesized from 4-chlorobenzaldehyde (**1h**) and 2-morpholinoethan-1-amine (**5**) in 77% yield [Scheme 1 (1)]. A D3 receptor intermediate **11** was also synthesized from 4-bromobenzaldehyde (**1j**) and an amine intermediate **10** in 65% yield; compound **11** was converted to D3 receptor GR103691 following a known procedure^{17a} [Scheme 1 (2)]. These results indicate that the developed method for the synthesis of amides is applicable to the synthesis of natural products and pharmaceutically and industrially relevant compounds.


Next, a one-pot method was investigated for the synthesis of esters from aldehydes and alcohols instead of amines. Although various alcohols, such as methanol, ethanol, isopropanol, hexanol, benzyl alcohol, and phenol, were tried, only reaction with methanol afforded the corresponding methyl benzoate **12** in a reasonable yield (Scheme 2).

Table 3. Amide Synthesis from Aldehydes via Acid Chlorides: Substrate Scope with Respect to Amines^{a,b}


^aReaction scale: **1** (1.0 mmol), amine (1.5 mmol). ^bIsolated yields based on the average of two runs.

On the basis of the results of the above-mentioned studies, a plausible mechanism is proposed for the synthesis of amides using benzaldehyde **1a** and benzyl amine outlined in Figure 2.¹⁸ The photoexcitation of [Ru^{II}(bpy)₃]²⁺ produces the metal-to-ligand charge-transfer excited state [Ru^{III}bpy^{•-}(bpy)₂]²⁺, which is oxidatively quenched by a single-electron transfer to tBuOOH, generating the key intermediates tBuO[•] and ⁻OH, along with [Ru^{III}(bpy)₃]³⁺. Hydrogen abstraction by tBuO[•] from benzaldehyde (**1a**) affords acyl radical **2a'** and tBuOH.¹¹ This acyl radical further abstracts a Cl radical from NCS, generating succinimide radical intermediate **A** and benzoyl chloride (**2a**). Then, the addition of benzyl amine to the

Scheme 1. Synthesis of Antidepressant Moclobemide 6 and D3 Receptor GR103691



Scheme 2. Visible-Light-Mediated Ester Synthesis from Benzaldehyde and Methanol



reaction mixture affords *N*-benzylbenzamide (3a) by a substitution reaction. On the other hand, a single-electron transfer

from $t\text{BuOO}^-$, which is generated by the deprotonation of $t\text{BuOOH}$ with OH^- , to $[\text{Ru}^{\text{III}}(\text{bpy})_3]^{3+}$ regenerates the photocatalyst, $[\text{Ru}^{\text{II}}(\text{bpy})_3]^{2+}$.¹¹ The conversion of aldehydes to acid chlorides works even with a substoichiometric amount of TBHP (Table 1, entries 10 and 11); this is supported by the following pathways: (a) $t\text{BuOO}\cdot$ abstracts a $\text{H}\cdot$ from aldehyde 1a, affording $2a'$ intermediate and regenerating TBHP; (b) the $\text{H}\cdot$ abstraction by succinimide radical A from aldehyde C–H also generates $2a'$ with succinimide B.




Figure 2. Proposed mechanism.

In conclusion, we developed an efficient one-pot method for the synthesis of amides from aldehydes and amines. The amide bonds were constructed from aldehydes via the in situ formation of acid chlorides using Ru(bpy)₃Cl₂ as the photocatalyst and TBHP as the oxidant under visible-light irradiation. The new method is practical and efficient for the synthesis of amides from different benzaldehyde derivatives and diverse aliphatic and aromatic amines. The process was successfully applied to the synthesis of drug molecules, an antidepressant moclobemide and a D3 receptor intermediate.

EXPERIMENTAL SECTION

General Experimental Procedure for Amide Synthesis. An oven-dried resealable tube, equipped with a magnetic stir bar, was charged with an aldehyde (1.0 mmol), Ru(bpy)₃Cl₂ (1 mol %), TBHP (1.3 equiv), NCS (3.0 equiv), and CH₃CN (0.25 M). The tube was stoppered with a silicone septa screw cap and placed under blue LEDs at room temperature. After 24 h irradiation, amine (1.5 equiv) was added, and the reaction was stirred for 3 h. The progress of the reaction was monitored by TLC and GC. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate. After the aqueous workup, the organic layers were combined, dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash column chromatography, affording the desired amide product.

In the reactions for **4h**, **6**, and **11**, before the addition of amines, the reaction mixture was concentrated in vacuo, dissolved in a 1% TEA/hexane solution, and filtered.

Analytic Data for Amides. *N*-Benzylbenzamide (**3a**).^{5e} White solid (165 mg, 78%); ¹H NMR (600 MHz, CDCl₃) δ 7.77 (d, *J* = 7.8 Hz, 2H), 7.48–7.42 (m, 1H), 7.40–7.34 (m, 2H), 7.34–7.28 (m, 4H), 7.28–7.24 (m, 1H), 6.84 (bs, 1H), 4.57 (d, *J* = 6.0 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 167.6, 138.5, 134.5, 131.6, 128.8, 128.7, 127.9, 127.6, 127.2, 44.2. IR (neat): ν_{max} = 3318, 3058, 1639, 1538, 1310, 691 cm⁻¹; R_f 0.45 (hexane/ethyl acetate 2:1).

N-Benzyl-2-methylbenzamide (**3b**).^{19b} White solid (146 mg, 65%); ¹H NMR (600 MHz, CDCl₃) δ 7.39–7.27 (m, 7H), 7.24–7.15 (m, 2H), 6.20 (bs, 1H), 4.60 (d, *J* = 6.0 Hz, 2H), 2.44 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 170.0, 138.1, 136.5, 136.1, 131.1, 130.0, 128.8, 127.8, 127.2, 126.7, 125.7, 43.9, 19.8. IR (neat): ν_{max} = 3308, 1647, 1541, 1200, 1000, 735, 698 cm⁻¹; R_f 0.36 (hexane/ethyl acetate 3:1).

N-Benzyl-4-methylbenzamide (**3c**).^{5e} White solid (158 mg, 70%); ¹H NMR (600 MHz, CDCl₃) δ 7.69 (d, *J* = 8.4 Hz, 2H), 7.38–7.32 (m, 4H), 7.31–7.27 (m, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.47 (bs, 1H), 4.63 (d, *J* = 6.0 Hz, 2H), 2.39 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 167.5, 142.2, 138.5, 131.7, 129.4, 129.0, 128.1, 127.8, 127.2, 44.3, 21.6. IR (neat): ν_{max} = 3309, 1637, 1544, 1506, 907, 841, 721 cm⁻¹; R_f 0.36 (hexane/ethyl acetate 3:1).

N-Benzyl-4-isopropylbenzamide (**3d**). White solid (182 mg, 72%); ¹H NMR (600 MHz, CDCl₃) δ 7.73 (d, *J* = 8.4 Hz, 2H), 7.38–7.33 (m, 4H), 7.32–7.26 (m, 1H), 7.28 (d, *J* = 8.4 Hz, 2H), 6.39 (bs, 1H), 4.65 (d, *J* = 6.0 Hz, 2H), 2.95 (hept, *J* = 7.2 Hz, 1H), 1.26 (d, *J* = 6.6 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 167.5, 153.0, 138.5, 132.1, 129.0, 128.1, 127.8, 127.3, 126.9, 44.3, 34.3, 24.0. IR (neat): ν_{max} = 3319, 1636, 1541, 1506, 1311, 852, 697 cm⁻¹; R_f 0.45 (hexane/ethyl acetate 3:1).

N-Benzyl-4-(*tert*-butyl)benzamide (**3e**).^{19f} White solid (227 mg, 85%); ¹H NMR (600 MHz, CDCl₃) δ 7.77 (d, *J* = 8.4 Hz, 2H), 7.43 (d, *J* = 8.4 Hz, 2H), 7.37–7.32 (m, 4H), 7.31–7.28 (m, 1H), 6.48 (bs, 1H), 4.64 (d, *J* = 6.0 Hz, 2H), 1.44 (s, 9H). ¹³C NMR (151 MHz, CDCl₃) δ 167.4, 150.1, 138.3, 132.6, 129.0, 128.1, 127.8, 127.2, 126.5, 44.3, 40.3, 26.7. IR (neat): ν_{max} = 3318, 1732, 1708, 1540, 1152, 698, 645 cm⁻¹; R_f 0.52 (hexane/ethyl acetate 2:1).

N-Benzyl-[1,1'-biphenyl]-4-carboxamide (**3f**).^{19c} White solid (239 mg, 83%); ¹H NMR (600 MHz, CDCl₃) δ 7.87 (d, *J* = 8.4 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 2H), 7.61–7.57 (m, 2H), 7.47–7.43 (m, 2H), 7.40–7.37 (m, 1H), 7.37–7.33 (m, 4H), 7.32–7.28 (m, 1H), 6.66 (bs, 1H), 4.66 (d, *J* = 6.0 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 167.3, 144.5, 140.1, 138.4, 133.1, 129.1, 129.0, 128.2, 128.1, 127.8,

127.7, 127.4, 127.4, 44.3. IR (neat): ν_{max} = 3326, 1701, 1636, 1541, 745, 692 cm⁻¹; R_f 0.52 (hexane/ethyl acetate 2:1).

N-Benzyl-4-fluorobenzamide (**3g**).^{7e} White solid (193 mg, 84%); ¹H NMR (600 MHz, CDCl₃) δ 7.79 (dd, *J*_{H-F} = 9.0 Hz, *J*_{H-H} = 5.4 Hz, 2H), 7.36–7.31 (m, 4H), 7.31–7.27 (m, 1H), 7.07 (dd, *J*_{H-F} = 9.0 Hz, *J*_{H-H} = 8.4 Hz, 2H), 6.62 (bs, 1H), 4.60 (d, *J* = 6.0 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 166.6, 164.9 (d, *J* = 252.17 Hz), 138.3, 130.7 (d, *J* = 3.02 Hz), 129.5 (d, *J* = 9.06 Hz), 129.0, 128.1, 127.8, 115.8, 115.7, 44.4. IR (neat): ν_{max} = 1654, 1497, 1264, 906, 726 cm⁻¹; R_f 0.39 (hexane/ethyl acetate 3:1).

N-Benzyl-4-chlorobenzamide (**3h**).^{5e} White solid (204 mg, 83%); ¹H NMR (600 MHz, CDCl₃) δ 7.72 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.37–7.31 (m, 4H), 7.31–7.27 (m, 1H), 6.54 (bs, 1H), 4.61 (d, *J* = 5.4 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 166.5, 138.2, 138.0, 132.9, 129.0, 128.6, 128.1, 127.9, 44.4. IR (neat): ν_{max} = 3309, 1637, 1552, 1487, 1320, 1013, 849, 711, 669 cm⁻¹; R_f 0.58 (hexane/ethyl acetate 2:1).

N-Benzyl-2,4-dichlorobenzamide (**3i**). White solid (216 mg, 77%); ¹H NMR (600 MHz, CDCl₃) δ 7.58 (d, *J* = 7.8 Hz, 1H), 7.39 (d, *J* = 2.4 Hz, 1H), 7.38–7.32 (m, 4H), 7.32–7.26 (m, 2H), 6.65 (bs, 1H), 4.61 (d, *J* = 6.0 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 165.6, 137.7, 137.0, 133.5, 131.7, 131.4, 130.2, 129.0, 128.0, 127.9, 127.7, 44.5. IR (neat): ν_{max} = 3263, 1644, 1587, 1540, 830, 743, 693 cm⁻¹; R_f 0.58 (hexane/ethyl acetate 2:1).

N-Benzyl-4-bromobenzamide (**3j**).^{7e} White solid (252 mg, 87%); ¹H NMR (600 MHz, CDCl₃) δ 7.65 (d, *J* = 8.4 Hz, 2H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.38–7.31 (m, 4H), 7.31–7.28 (m, 1H), 6.42 (bs, 1H), 4.62 (d, *J* = 5.4 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 166.6, 138.1, 133.4, 132.0, 129.1, 128.8, 128.2, 128.0, 126.5, 44.5. IR (neat): ν_{max} = 3311, 1638, 1549, 1322, 1011, 847, 669 cm⁻¹; R_f 0.58 (hexane/ethyl acetate 2:1).

N-Benzyl-4-cyanobenzamide (**3k**).^{19c} White solid (187 mg, 79%); ¹H NMR (600 MHz, CDCl₃) δ 7.87 (d, *J* = 8.4 Hz, 2H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.36–7.24 (m, 5H), 7.23 (bs, 1H), 4.58 (d, *J* = 5.6 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 165.9, 138.2, 137.8, 132.4, 128.8, 127.9, 127.8, 118.1, 114.9, 44.2. IR (neat): ν_{max} = 3309, 1708, 1540, 1158, 906, 722 cm⁻¹; R_f 0.41 (hexane/ethyl acetate 3:1).

N-Benzyl-3-(trifluoromethyl)benzamide (**3l**).^{19d} White solid (212 mg, 76%); ¹H NMR (600 MHz, CDCl₃) δ 8.05 (t, *J* = 1.8 Hz, 1H), 7.96 (d, *J* = 7.8 Hz, 1H), 7.74 (d, *J* = 7.8 Hz, 1H), 7.53 (dd, *J* = 7.8 Hz, 1H), 7.37–7.32 (m, 4H), 7.32–7.27 (m, 1H), 6.77 (bs, 1H), 4.62 (d, *J* = 5.4 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 166.2, 138.0, 135.4, 131.3 (q, *J* = 32.78 Hz), 130.5, 129.4, 129.0, 128.3 (q, *J* = 3.6 Hz), 128.1, 128.0, 124.3 (q, *J* = 3.6 Hz), 123.9 (q, *J* = 272.71 Hz), 44.5. IR (neat): ν_{max} = 3295, 1641, 1541, 1333, 1278, 1168, 1125, 696 cm⁻¹; R_f 0.41 (hexane/ethyl acetate 3:1).

N-Phenylbenzamide (**4a**).^{5b} White solid (134 mg, 68%); ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.03 (bs, 1H), 7.93 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.75 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.49 (tt, *J* = 7.2, 1.2 Hz, 1H), 7.44 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.27 (dd, *J* = 8.4, 7.2 Hz, 2H), 7.04 (tt, *J* = 7.2, 1.2 Hz, 1H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 164.7, 137.9, 134.0, 130.0, 127.2, 126.9, 126.4, 122.4, 119.3. IR (neat): ν_{max} = 3347, 1652, 1525, 1407, 1216, 827, 716, 644 cm⁻¹; R_f 0.41 (hexane/ethyl acetate 3:1).

N-(2-Bromophenyl)benzamide (**4b**).^{19g} White solid (177 mg, 64%); ¹H NMR (600 MHz, CDCl₃) δ 8.56 (dd, *J* = 8.4, 1.2 Hz, 1H), 8.47 (bs, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.63–7.55 (m, 2H), 7.55–7.49 (m, 2H), 7.38 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1H), 7.02 (ddd, *J* = 7.8, 7.2, 1.2 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 165.5, 136.0, 134.8, 132.5, 132.4, 129.2, 128.8, 127.3, 125.5, 122.0, 113.9. IR (neat): ν_{max} = 3280, 1653, 1529, 1435, 1308, 750, 706 cm⁻¹; R_f 0.51 (hexane/ethyl acetate 5:1).

N-(4-Fluorophenyl)benzamide (**4c**).^{5b} White solid (142 mg, 66%); ¹H NMR (600 MHz, DMSO-*d*₆) δ 10.22 (bs, 1H), 7.97–7.90 (m, 2H), 7.79 (dd, *J*_{H-F} = 9 Hz, *J*_{H-H} = 5.4 Hz, 2H), 7.53 (tt, *J* = 7.2, 1.6 Hz, 1H), 7.48 (m, 2H), 7.11–7.05 (m, 2H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 163.9, 156.8 (d, *J* = 241.6), 133.9, 133.3, 129.8, 126.6, 126.0, 120.6, 113.3 (d, *J* = 22.65). IR (neat): ν_{max} = 3343, 1654, 1537, 1438, 750, 690 cm⁻¹; R_f 0.45 (hexane/ethyl acetate 3:1).

N-(2-Bromopyridin-3-yl)benzamide (**4d**).^{19a} White solid (161 mg, 58%); ¹H NMR (600 MHz, CDCl₃) δ 8.86 (dd, *J* = 8.4, 1.8 Hz, 1H), 8.49 (bs, 1H), 8.13 (dd, *J* = 4.8, 1.8 Hz, 1H), 7.93 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.60 (tt, *J* = 7.5, 1.6 Hz, 1H), 7.53 (dd, *J* = 7.8, 7.7 Hz, 2H), 7.32 (dd, *J* = 7.8, 4.8 Hz, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 165.7, 144.8, 134.0, 133.9, 133.6, 132.8, 130.3, 129.3, 128.9, 127.3, 123.9. IR (neat): ν_{max} = 3403, 1684, 1508, 1488, 1381, 1297, 1048, 706 cm⁻¹; *R*_f 0.34 (hexane/ethyl acetate 3:1).

N-(4-Methoxybenzyl)benzamide (**4e**).^{4f} White solid (198 mg, 82%); ¹H NMR (600 MHz, CDCl₃) δ 7.78 (d, *J* = 8.4 Hz, 2H), 7.48 (tt, *J* = 7.5, 1.4 Hz, 1H), 7.41 (dd, *J* = 7.8, 7.7 Hz, 2H), 7.28 (dd, *J* = 8.4, 6.6 Hz, 2H), 6.88 (d, *J* = 8.4 Hz, 2H), 6.40 (s, 1H), 4.57 (d, *J* = 6.0 Hz, 2H), 3.80 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 167.5, 159.3, 134.7, 131.7, 130.5, 129.5, 128.8, 127.1, 114.4, 55.5, 43.9. IR (neat): ν_{max} = 3308, 3062, 1636, 1534, 1511, 1301, 1246, 1033, 695 cm⁻¹; *R*_f 0.36 (hexane/ethyl acetate 2:1).

N-(4-Fluorobenzyl)benzamide (**4f**).^{19c} White solid (181 mg, 79%); ¹H NMR (600 MHz, CDCl₃) δ 7.81–7.77 (m, 2H), 7.51 (t, *J* = 7.5, 1.4 Hz, 1H), 7.44 (dd, *J* = 7.8, 7.7 Hz, 2H), 7.33 (dd, *J* = 8.4, 5.4 Hz, 2H), 7.04 (dd, *J* = 8.7, 2H), 6.41 (bs, 1H), 4.62 (d, *J* = 5.4 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 167.5, 163.5 (d, *J* = 32.6 Hz), 134.4 (d, *J* = 48 Hz), 131.9, 129.8 (d, *J* = 10 Hz), 128.9, 127.1, 115.9, 115.8, 43.6. IR (neat): ν_{max} = 3310, 1637, 1541, 1510, 1222, 692 cm⁻¹; *R*_f 0.43 (hexane/ethyl acetate 2:1).

N-Hexylbenzamide (**4g**).^{7d} Colorless liquid (150 mg, 73%); ¹H NMR (600 MHz, CDCl₃) δ 7.76 (dd, *J* = 8.4, 7.2 Hz, 2H), 7.44 (tt, *J* = 7.2, 1.7 Hz, 1H), 7.36 (dd, *J* = 7.8 Hz, 2H), 6.60 (bs, 1H), 3.40 (td, *J* = 7.2, 6.0 Hz, 2H), 1.57 (tt, *J* = 7.2 Hz, 2H), 1.40–1.30 (m, 2H), 1.30–1.23 (m, 4H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 167.8, 135.0, 131.3, 128.6, 127.0, 40.3, 31.6, 29.7, 26.8, 22.7, 14.1. IR (neat): ν_{max} = 3310, 1635, 1540, 1490, 1309, 693 cm⁻¹; *R*_f 0.40 (hexane/ethyl acetate 3:1).

N-(2-(Diethylamino)ethyl)benzamide (**4h**).^{19c} Colorless liquid (134 mg, 61%); ¹H NMR (600 MHz, CDCl₃) δ 8.77 (bs, 1H), 8.01 (dd, *J* = 8.4, 1.2 Hz, 2H), 7.44 (tt, *J* = 7.5, 1.6 Hz, 1H), 7.39 (dd, *J* = 7.2, 6.0 Hz, 2H), 3.84 (dd, *J* = 10.8, 6.0 Hz, 2H), 3.22 (t, *J* = 5.4 Hz, 2H), 3.11 (q, *J* = 7.2 Hz, 4H), 1.34 (t, *J* = 7.2 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 167.9, 133.3, 132.0, 128.7, 127.7, 53.0, 48.5, 36.0, 9.1. IR (neat): ν_{max} = 3363, 1637, 1539, 1488, 1308, 694 cm⁻¹; *R*_f 0.42 (ethyl acetate/methanol 2:1).

Phenyl(piperidin-1-yl)methanone (**4i**).^{5e} Colorless liquid (119 mg, 63%); ¹H NMR (600 MHz, CDCl₃) δ 7.43–7.35 (m, 5H), 3.77–3.65 (m, 2H), 3.40–3.28 (m, 2H), 1.76–1.60 (m, 4H), 1.59–1.41 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 170.6, 136.5, 129.5, 128.5, 127.0, 49.0, 43.4, 26.7, 25.8, 24.7. IR (neat): ν_{max} = 1713, 1625, 1444, 1274, 1003, 707 cm⁻¹; *R*_f 0.37 (hexane/ethyl acetate 2:1).

N,N-Dibutylbenzamide (**4j**).^{7a} Colorless liquid (145 mg, 62%); ¹H NMR (600 MHz, CDCl₃) δ 7.38–7.30 (m, 5H), 3.48 (t, *J* = 7.8 Hz, 2H), 3.18 (t, *J* = 7.8 Hz, 2H), 1.65 (tt, *J* = 7.8 Hz, 2H), 1.46 (tt, *J* = 7.8 Hz, 2H), 1.43–1.32 (m, 2H), 1.21–1.05 (m, 2H), 0.97 (t, *J* = 7.2 Hz, 3H), 0.76 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 171.4, 137.2, 128.8, 128.1, 126.2, 48.6, 44.3, 30.6, 29.5, 20.1, 19.5, 13.7, 13.4. IR (neat): ν_{max} = 2956, 1627, 1421, 1296, 1100, 698 cm⁻¹; *R*_f 0.49 (hexane/ethyl acetate 5:1).

4-Chloro-*N*-(2-morpholinoethyl)benzamide (**6**).¹⁶ White solid (207 mg, 77%); ¹H NMR (600 MHz, CDCl₃) δ 7.71 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 6.79 (bs, 1H), 3.75–3.65 (m, 4H), 3.58–3.50 (m, 2H), 2.63–2.56 (m, 2H), 2.57–2.43 (m, 4H). ¹³C NMR (151 MHz, CDCl₃) δ 166.5, 137.8, 133.2, 129.0, 128.6, 67.1, 57.0, 53.5, 36.3. IR (neat): ν_{max} = 3309, 1646, 1541, 1487, 1312, 1116, 1093, 860 cm⁻¹; *R*_f 0.50 (ethyl acetate/methanol 4:1).

2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)isoindoline-1,3-dione (**9**).^{17b} Yellowish solid; ¹H NMR (600 MHz, CDCl₃) δ 7.82 (dd, *J* = 5.4, 3.0 Hz, 2H), 7.69 (dd, *J* = 5.4, 3.0 Hz, 2H), 6.97 (ddd, *J* = 7.8, 7.2, 2.4 Hz, 1H), 6.92 (dd, *J* = 7.8, 2.4 Hz, 1H), 6.89 (ddd, *J* = 7.5, 1.4 Hz, 1H), 6.83 (dd, *J* = 7.8, 1.2 Hz, 1H), 3.84 (s, 3H), 3.71 (t, *J* = 7.8 Hz, 2H), 3.21–2.95 (m, 4H), 2.73–2.55 (m, 4H), 2.44 (t, *J* = 7.8 Hz, 2H), 1.72 (tt, *J* = 7.8 Hz, 2H), 1.57 (tt, *J* = 7.8 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 168.6, 152.4, 141.5, 134.0, 132.3, 123.3, 123.0, 121.1, 118.3, 111.3, 58.2, 55.4, 53.5, 50.7, 38.0, 26.7, 24.3. IR

(neat): ν_{max} = 3280, 1653, 1529, 1435, 1308, 750, 706 cm⁻¹; *R*_f 0.68 (ethyl acetate/methanol 10:1).

4-(4-(2-Methoxyphenyl)piperazin-1-yl)butan-1-amine (**10**).^{17b} Greenish yellow viscous liquid; ¹H NMR (600 MHz, CDCl₃) δ 6.98 (dd, *J* = 7.8, 7.2 Hz, 1H), 6.94 (d, *J* = 7.6 Hz, 1H), 6.91 (dd, *J* = 7.8, 7.2 Hz, 1H), 6.85 (d, *J* = 7.8 Hz, 1H), 3.85 (s, 3H), 3.25–3.0 (m, 4H), 2.73 (t, *J* = 7.2 Hz, 2H), 2.70–2.58 (m, 4H), 2.42 (t, *J* = 7.2 Hz, 2H), 2.33 (bs, 2H), 1.58 (tt, *J* = 7.2 Hz, 2H), 1.51 (tt, *J* = 7.2 Hz, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 152.5, 141.5, 123.1, 121.2, 118.4, 111.4, 58.7, 55.6, 53.6, 50.8, 42.0, 31.6, 24.6. IR (neat): ν_{max} = 1499, 1450, 1238, 1118, 1025, 746 cm⁻¹; *R*_f 0.52 (chloroform/methanol/ammonia solution 85:13:2).

4-Bromo-*N*-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-benzamide (**11**).^{17b} Light green solid (290 mg, 65%); ¹H NMR (600 MHz, CDCl₃) δ 7.63 (d, *J* = 8.4 Hz, 2H), 7.54 (d, *J* = 8.4 Hz, 2H), 7.0 (dd, *J* = 7.6 Hz, 1H), 6.92 (dd, *J* = 7.6 Hz, 1H), 6.87 (d, *J* = 7.8 Hz, 1H), 6.85 (d, *J* = 7.8 Hz, 1H), 3.85 (s, 3H), 3.46 (td, *J* = 6.0 Hz, 2H), 3.15–2.95 (m, 4H), 2.70–2.55 (m, 4H), 2.46 (t, *J* = 7.2 Hz, 2H), 1.72–1.58 (m, 4H). ¹³C NMR (151 MHz, CDCl₃) δ 167.0, 152.4, 141.3, 134.1, 131.9, 128.8, 126.0, 123.2, 121.2, 118.36, 111.38, 58.2, 55.6, 53.61, 50.63, 40.3, 27.6, 24.6. IR (neat): ν_{max} = 3289, 1634, 1541, 1499, 1239, 1010, 729 cm⁻¹; *R*_f 0.45 (ethyl acetate/methanol 4:1).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02726.

Characterization and spectral data of compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: ejcho@cau.ac.kr. Phone: (82)-2-820-5946.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF-2014R1A1A1A05003274, NRF-2014-011165, and NRF-2012M3A7B4049657).

■ REFERENCES

- (1) (a) Humphrey, J. M.; Chamberlin, A. R. *Chem. Rev.* **1997**, *97*, 2243. (b) Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. *J. Comb. Chem.* **1999**, *1*, 55. (c) Kleeman, A.; Engel, J. *Pharmaceutical Substances: Syntheses, Patents, Applications*, 4th ed.; Thieme: Stuttgart, 2001. (d) Fraxedas, J. *Molecular Organic Materials: From Molecules to Crystalline Solids*; Cambridge University Press: Cambridge, U.K., 2006. (e) Allen, C. L.; Williams, J. M. J. *Chem. Soc. Rev.* **2011**, *40*, 3405. (f) Pattabiraman, V. R.; Bode, J. W. *Nature* **2011**, *480*, 471. (g) Wilson, R. M.; Stockdill, J. L.; Wu, X.; Li, X.; Vadola, P. A.; Park, P. K.; Wang, P.; Danishefsky, S. J. *Angew. Chem.* **2012**, *124*, 2888; *Angew. Chem., Int. Ed.* **2012**, *51*, 2834.
- (2) Valeur, E.; Bradley, M. *Chem. Soc. Rev.* **2009**, *38*, 606.
- (3) Roy, S.; Roy, S.; Gribble, G. W. *Tetrahedron* **2012**, *68*, 9867.
- (4) For some examples of amide synthesis using NHC, see: (a) Bode, J. W.; Sohn, S. S. *J. Am. Chem. Soc.* **2007**, *129*, 13798. (b) Guin, J.; De Sarkar, S.; Grimme, S.; Studer, A. *Angew. Chem., Int. Ed.* **2008**, *47*, 8727. (c) Zhao, J.; Mück-Lichtenfeld, C.; Studer, A. *Adv. Synth. Catal.* **2013**, *355*, 1098. (d) Alanthadka, A.; Maheswari, C. U. *Adv. Synth. Catal.* **2015**, *357*, 1199. (e) Flanigan, D. M.; Romanov-Michailidis, F.; White, N. A.; Rovis, T. *Chem. Rev.* **2015**, *115*, 9307. (f) Chen, C.; Kim, M. H.; Hong, S. H. *Org. Chem. Front.* **2015**, *2*, 241.
- (5) For some examples of amide synthesis directly from amine and aldehydes, see: (a) Reddy, K. R.; Maheswari, C. U.; Venkateshwar, M.; Kantam, M. L. *Eur. J. Org. Chem.* **2008**, *2008*, 3619. (b) Wang, J.; Li, J.; Xu, F.; Shen, Q. *Adv. Synth. Catal.* **2009**, *351*, 1363. (c) Li, G.-L.;

Kung, K. K.-Y.; Wong, M.-K. *Chem. Commun.* **2012**, *48*, 4112. (d) Lee, J.; Muthaiah, S. K.; Hong, S. H. *Adv. Synth. Catal.* **2014**, *356*, 2653. (e) Miyamura, H.; Min, H.; Soulé, J.-F.; Kobayashi, S. *Angew. Chem., Int. Ed.* **2015**, *54*, 7564.

(6) For some examples of amide synthesis from amine salts and aldehydes, see: (a) Yoo, W.-J.; Li, C.-J. *J. Am. Chem. Soc.* **2006**, *128*, 13064. (b) Ghosh, S. C.; Ngiam, J. S. Y.; Seayad, A. M.; Tuan, D. T.; Chai, C. L. L.; Chen, A. *J. Org. Chem.* **2012**, *77*, 8007. (c) Saberi, D.; Heydari, A. *Appl. Organomet. Chem.* **2014**, *28*, 101.

(7) For some examples of amide synthesis using RR'N-Cl and aldehydes, see: (a) Porcheddu, A.; Luca, L. D. *Adv. Synth. Catal.* **2012**, *354*, 2949. (b) Cadoni, R.; Porcheddu, A.; Giacomelli, G.; De Luca, L. *Org. Lett.* **2012**, *14*, 5014. (c) Zhou, B.; Du, J.; Yang, Y.; Li, Y. *Org. Lett.* **2013**, *15*, 2934. (d) Vanjari, R.; Guntreddi, T.; Singh, K. N. *Green Chem.* **2014**, *16*, 351. (e) Achar, T. K.; Mal, P. *J. Org. Chem.* **2015**, *80*, 666.

(8) Examples of amide synthesis from aldehyde via activating groups; see: (a) Yao, H.; Yamamoto, K. *Chem.—Asian J.* **2012**, *7*, 1542. (b) Yao, H.; Tang, Y.; Yamamoto, K. *Tetrahedron Lett.* **2012**, *53*, 5094. (c) Pilo, M.; Porcheddu, A.; De Luca, L. *Org. Biomol. Chem.* **2013**, *11*, 8241. (d) Dettori, G.; Gaspa, S.; Porcheddu, A.; De Luca, L. *Adv. Synth. Catal.* **2014**, *356*, 2709.

(9) Tan, B.; Toda, N.; Barbas, C. F. *Angew. Chem., Int. Ed.* **2012**, *51*, 12538.

(10) Recently, the Maity group reported a cross-dehydrogenative coupling process of aldehydes with *N*-hydroxyimides, and an example for the amide synthesis was shown in the work. See: Dinda, M.; Bose, C.; Ghosh, T.; Maity, S. *RSC Adv.* **2015**, *5*, 44928.

(11) TBHP under visible light: Li, J.; Wang, D. *Z. Org. Lett.* **2015**, *17*, 5260.

(12) TBHP for aldehyde C–H bond activation; see: (a) Barton, D. H. R.; Le Gloahec, V. N. *Tetrahedron* **1998**, *54*, 15457. (b) Wei, W.; Zhang, C.; Xu, Y.; Wan, X. *Chem. Commun.* **2011**, *47*, 10827. (c) Khatun, N.; Santra, S. K.; Banerjee, A.; Patel, B. K. *Eur. J. Org. Chem.* **2015**, *2015*, 1309. (d) Lv, L.; Xi, H.; Bai, X.; Li, Z. *Org. Lett.* **2015**, *17*, 4324. (e) Pramanik, S.; Reddy, R. R.; Ghorai, P. *Org. Lett.* **2015**, *17*, 1393.

(13) For selected recent reviews on photoredox catalysis, see: (a) Fagnoni, M.; Dondi, D.; Ravelli, D.; Albin, A. *Chem. Rev.* **2007**, *107*, 2725. (b) Ravelli, D.; Dondi, D.; Fagnoni, M.; Albin, A. *Chem. Soc. Rev.* **2009**, *38*, 1999. (c) Zeitler, K. *Angew. Chem., Int. Ed.* **2009**, *48*, 9785. (d) Yoon, T. P.; Ischay, M. A.; Du, J. *Nat. Chem.* **2010**, *2*, 527. (e) Narayanam, J. M. R.; Stephenson, C. R. J. *Chem. Soc. Rev.* **2011**, *40*, 102. (f) Shi, L.; Xia, W. J. *Chem. Soc. Rev.* **2012**, *41*, 7687. (g) Tucker, J. W.; Stephenson, C. R. J. *J. Org. Chem.* **2012**, *77*, 1617. (h) Xuan, J.; Xiao, W. J. *Angew. Chem., Int. Ed.* **2012**, *51*, 6828. (i) Noël, T.; Wang, X.; Hessel, V. *Chim. Oggi.* **2013**, *31*, 10. (j) Prier, C. K.; Rankic, D. A.; MacMillan, D. W. C. *Chem. Rev.* **2013**, *113*, 5322.

(14) Examples of our recent previous works by visible-light-induced photocatalysis; see: (a) Iqbal, N.; Choi, S.; Kim, E. J.; Cho, E. J. *J. Org. Chem.* **2012**, *77*, 11383. (b) Iqbal, N.; Jung, J.; Park, S.; Cho, E. J. *Angew. Chem., Int. Ed.* **2014**, *53*, 539. (c) Yu, C.; Iqbal, N.; Park, S.; Cho, E. J. *Chem. Commun.* **2014**, *50*, 12884. (d) Choi, W. J.; Choi, S.; Ohkubo, K.; Fukuzumi, S.; Cho, E. J.; You, Y. *Chem. Sci.* **2015**, *6*, 1454. (e) Choi, S.; Chatterjee, T.; Choi, W. J.; You, Y.; Cho, E. J. *ACS Catal.* **2015**, *5*, 4796. (f) Iqbal, N.; Cho, E. J. *Adv. Synth. Catal.* **2015**, *357*, 2187.

(15) (a) Cramer, R. *J. Am. Chem. Soc.* **1957**, *79*, 6215. (b) Chatgililoglu, C.; Crich, D.; Komatsu, M.; Ryu, I. *Chem. Rev.* **1999**, *99*, 1991. (c) Tzirakis, M. D.; Orfanopoulos, M. *J. Am. Chem. Soc.* **2009**, *131*, 4063.

(16) Angst, J.; Amrein, R.; Stabl, M. *J. Clin. Psychopharmacol.* **1995**, *15*, 16S.

(17) D3 receptor intermediate: (a) Murray, P. J.; Harrison, L. A.; Johnson, M. R.; Robertson, G. M.; Scopes, D. I. C.; Bull, D. R.; Graham, E. A.; Hayes, A. G.; Kilpatrick, G. J.; Daas, I. D.; Large, C.; Sheehan, M. J.; Stubbs, C. M.; Turpin, M. P. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 219. (b) Hocke, C.; Prante, O.; Löber, S.; Hübner, H.; Gmeiner, P.; Kuwert, T. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4819.

(18) : The reaction was suppressed in the presence of TEMPO, indicating that free-radical species are involved in the transformation.

(19) (a) Adam, M. S. S.; Kühn, O.; Kindermann, M. K.; Heinicke, J. W.; Jones, P. G. *Tetrahedron* **2008**, *64*, 7960. (b) Roberts, B.; Liptrot, D.; Alcaraz, L.; Luker, T.; Stocks, M. J. *Org. Lett.* **2010**, *12*, 4280. (c) Kulkarni, S. S.; Hu, X.; Manetsch, R. *Chem. Commun.* **2013**, *49*, 1193. (d) Li, F.; Qu, P.; Ma, J.; Zou, X.; Sun, C. *ChemCatChem* **2013**, *5*, 2178. (e) Ghosh, S. C.; Li, C. C.; Zeng, H. C.; Ngiam, J. S. Y.; Seayad, A. M.; Chen, A. *Adv. Synth. Catal.* **2014**, *356*, 475. (f) Lenstra, D. C.; Rutjes, F. P. J. T.; Mecinović, J. *Chem. Commun.* **2014**, *50*, 5763. (g) Fan, W.; Yang, Y.; Lei, J.; Jiang, Q.; Zhou, W. *J. Org. Chem.* **2015**, *80*, 8782.

NOTE ADDED AFTER ASAP PUBLICATION

Figure 2 contained an error in the version published ASAP on February 16, 2016. On February 24, 2016, in the catalytic cycle, Ru(III) was changed to Ru(II).